Literature DB >> 33633989

Evaluation of the diagnostic performance of contrast-enhanced ultrasound combined with BRAF V600E gene detection in nodules of unclear significance by thyroid fine-needle aspiration.

Xi Zhu1, Xuyang Peng2, Lei Zhu1, Lidan Xie3, Feng Cheng1, Bin Zhou1.   

Abstract

BACKGROUND: Our study aims to test the diagnostic performance of contrast-enhanced ultrasound (CEUS) combined with the detection of serine/threonine-protein kinase V600E (BRAF V600E) in nodules of unclear significance by thyroid fine-needle aspiration (FNA).
METHODS: From January 2015 to December 2019, 244 patients were subjected to ultrasonic strain imaging and elastography, CEUS, and BRAF V600E gene detection at Lishui Hospital of Zhejiang University. Thyroid FNA does not confirm the benignancy and malignancy of the thyroid nodules. With postoperative pathology as the gold standard, the diagnostic value of CEUS, BRAF V600E detection, and the combination in differentiating benign and malignant thyroid nodules were evaluated. The negative predictive value (NPV) and accuracy of CEUS, BRAF V600E detection, and the combination were calculated along with sensitivity, specificity, and positive predictive value (PPV).
RESULTS: In this study, the sensitivity, specificity, PPV, NPV, accuracy, and AUC of CEUS alone in predicting benign and malignant thyroid nodules were 69.8%, 94.9%, 98.6%, 37.4%, 73.8% and 0.884, respectively. The sensitivity, specificity, PPV, NPV, accuracy and AUC of BRAF V600E detection alone were 65.4%, 100%, 100%, 35.5%, 70.9% and 0.827, respectively. The sensitivity, specificity, PPV, NPV, accuracy and AUC of the combination were 73.2%, 94.9%, 98.7%, 40.2%, 76.6% and 0.923, respectively.
CONCLUSIONS: Therefore, compared with CEUS or BRAF V600E gene detection alone, the combination of CEUS and BRAF V600E gene detection has a higher sensitivity, NPV, and accuracy in the diagnosis of thyroid nodules. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  BRAF V600E gene; Thyroid nodule; contrast-enhanced; fine-needle aspiration; mutation

Year:  2021        PMID: 33633989      PMCID: PMC7882305          DOI: 10.21037/gs-20-705

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  24 in total

1.  Diagnostic value of contrast-enhanced ultrasound in solid thyroid nodules with and without enhancement.

Authors:  Qiong Wu; Yan Wang; Yi Li; Bing Hu; Zhi-Yan He
Journal:  Endocrine       Date:  2016-01-05       Impact factor: 3.633

2.  Thyroid cancer staging and genomics.

Authors:  Ashok R Shaha; R Michael Tuttle
Journal:  Ann Transl Med       Date:  2019-03

3.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

Authors:  Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

4.  Increasing incidence of thyroid cancer in Shanghai, China, 1983-2007.

Authors:  Youxin Wang; Wei Wang
Journal:  Asia Pac J Public Health       Date:  2012-02-16       Impact factor: 1.399

5.  BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

Authors:  Mingzhao Xing; William H Westra; Ralph P Tufano; Yoram Cohen; Eli Rosenbaum; Kerry J Rhoden; Kathryn A Carson; Vasily Vasko; Alexandr Larin; Giovanni Tallini; Sara Tolaney; Elizabeth H Holt; Pei Hui; Christopher B Umbricht; Shehzad Basaria; Marge Ewertz; Anthony P Tufaro; Joseph A Califano; Matthew D Ringel; Martha A Zeiger; David Sidransky; Paul W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  2005-09-20       Impact factor: 5.958

6.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.

Authors:  Paula Soares; Vítor Trovisco; Ana Sofia Rocha; Jorge Lima; Patrícia Castro; Ana Preto; Valdemar Máximo; Tiago Botelho; Raquel Seruca; Manuel Sobrinho-Simões
Journal:  Oncogene       Date:  2003-07-17       Impact factor: 9.867

7.  Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.

Authors:  Raquel Rodrigues; Lúcia Roque; Carla Espadinha; António Pinto; Rita Domingues; Joana Dinis; Ana Catarino; Teresa Pereira; Valeriano Leite
Journal:  Oncol Rep       Date:  2007-10       Impact factor: 3.906

8.  Utility of contrast-enhanced ultrasound for evaluation of thyroid nodules.

Authors:  Bo Zhang; Yu-Xin Jiang; Ji-Bin Liu; Meng Yang; Qing Dai; Qing-Li Zhu; Pin Gao
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

9.  A rapidly increasing trend of thyroid cancer incidence in selected East Asian countries: Joinpoint regression and age-period-cohort analyses.

Authors:  Runhua Li; Youqing Wang; Lingbin Du
Journal:  Gland Surg       Date:  2020-08

Review 10.  A Pragmatic Approach to the Indeterminate Thyroid Nodule.

Authors:  Krishna G Seshadri
Journal:  Indian J Endocrinol Metab       Date:  2017 Sep-Oct
View more
  2 in total

1.  The combination of BRAFV600E mutation and Chinese Thyroid Imaging Reporting and Data System is helpful in the management of AUS/FLUS thyroid nodules.

Authors:  Qiang Li; Lu Yang; Jianghong Lv; Lilong Xu; Murui Zhang; Shiyan Li
Journal:  Endocrine       Date:  2022-09-24       Impact factor: 3.925

2.  Differentiation of Thyroid Nodules (C-TIRADS 4) by Combining Contrast-Enhanced Ultrasound Diagnosis Model With Chinese Thyroid Imaging Reporting and Data System.

Authors:  Tiantong Zhu; Jiahui Chen; Zimo Zhou; Xiaofen Ma; Ying Huang
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.